Healthcare Professionals

Resolute Onyx™

Drug-Eluting Stent

DELIVERING ADVANCED DES TECHNOLOGY TO YOUR PATIENTS

The Resolute Onyx™ drug-eluting stent is an advanced workhorse DES ready for your challenging coronary cases.

Exceptional Deliverability   |   Broadest DES Size Matrix   |   Enhanced Visibility
 

Product Details

Two stent technologies join forces:
The only DES with Core Wire Technology and Continuous Sinusoid Technology

Continuous Sinusoid Technology
Flexible stent platform for outstanding flexibility and conformability

Continuous Sinusoid Technology

A single strand of cobalt alloy is formed into a sinusoid, wrapped in a helical pattern, and laser fused.

 

Core Wire Technology
Thinner struts with enhanced stent visibility for accurate stent placement

Core Wire Technology
 

Engineered for exceptional deliverability1

Thinner struts, a low crossing profile, and an enhanced delivery system enable exceptional deliverability — without compromising structural strength.

20% More Deliverable   |   36% More Pushable   |   11% Thinner Struts
 

Enhanced delivery system advances acute performance1

  • Greater flexibility
  • Lower crossing profile
  • Exceptional deliverability with PowerTrac Technology
A well balanced delivery system

BROADEST DES SIZE MATRIX

A generous 2.0–5.0-mm size range means you can deliver advanced workhorse performance to more patients — and all sizes are 5 F compatible.

Broadest DES Size Matrix

4.50- and 5.00-mm sizes are not available in OTW.

The first DES with 2.0-mm sizes

The first DES with 2.0-mm sizes

The first DES with 4.5- and 5.0-mm sizes

Expanding options for patients with extra-large vessels

Predictable performance in XLV sizes—even at maximum overexpansion6

Resolute Onyx DES has minimal foreshortening compared with Synergy™* DES — for precise placement while maintaining coating integrity.7

Resolute Onyx™ DES

5.0 mm x 18 mm
Deployed to 5.75 per IFU maximum overexpansion

Resolute Onyx vs. Synergy

Synergy™* DES

4.0 mm x 20 mm
Deployed to 5.75 per IFU maximum overexpansion

Synergy vs. Resolute Onyx

Ready to learn more? Download the brochure.


Enhanced visibility for accurate stent placement

A platinum iridium core within the cobalt alloy shell enhances radiopacity in thinner struts—without compromising structural strength.

Cobalt alloy shell   |   Platinum iridium core material
 

Meaningful clinical evidence-generation and extensive real-world use

Meaningful clinical evidence-generation and extensive real-world use

Stent performance that endures

RESOLUTE POOLED9 ANALYSIS OF STENT THROMBOSIS (ARC DEF/PROB) THROUGH FIVE YEARS

RESOLUTE POOLED Analysis of Stent Thrombosis (ARC DEF/PROB) Through Five Years

RESOLUTE POOLED9 ANALYSIS OUTCOMES THROUGH FIVE YEARS

RESOLUTE POOLED Analysis Outcomes Through Five Years

Resolute™ ZES (N = 7618)

Resolute Onyx DES — excellent safety in real-world study

Resolute Onyx DES — excellent safety in real-world study

One-Year Clinical Outcomes of Patients Treated with Resolute Onyx DES vs. Resolute Integrity™ DES : an Interim Study of HOST-ONYX and HOST-RESOLINTE Registries11

One-Year Clinical Outcomes of Patients Treated with Resolute Onyx DES vs. Resolute Integrity™ DES : an Interim Study of HOST-ONYX and HOST-RESOLINTE Registries

Product Specifications


1

Based on bench test data. May not be indicative of clinical performance.

2

Compared with Resolute Integrity DES in benchtop testing. Data on file at Medtronic. May not be indicative of clinical performance.

3

Bench test data on file at Medtronic. May not be indicative of clinical performance. Testing performed on smallest diameters available for Abbott Xience Alpine™*, Biotronik Orsiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, and Medtronic Resolute Onyx™ coronary stents. Biotronik Orsiro™* DES is not approved in the USA as of 21-FEB-2018. 

4

The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 2.0-mm stents to greater than 3.25 mm. Postdilation required for overexpansion.

5

Price et al. JACC Cardiovascular Interventions. 2017;10(14):1381–1388.
Study only powered for TLF clinical endpoint. Rates are taken from KM estimates

6

The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 4.5- and 5.0-mm stents to greater than 5.75 mm.

7

Based on bench test data. May not be indicative of clinical performance.

8

Based on net sales data of Resolute DES, Resolute Integrity DES, and Resolute Onyx DES through Q3FY2017.

9

Yeh et al. 5-year safety and efficacy of Resolute zotarolimus-eluting stent. JACC Cardiovascular Interventions. 2017;10:247–254.

10

Adapted from data published on http://www.ucr.uu.se/swedeheart/forskning-scaar/in-english/stent-reports as of March 28, 2017. ARC probable ST rates not reported in this analysis. Unadjusted, crude rates at different follow-up durations presented.

11

Kim et al. TCT 2017.

© 2018 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution in the USA only.